|
nasopharyngeal carcinoma |
41 |
|
whole-exome sequencing |
24 |
|
chemotherapy |
19 |
|
survival |
17 |
|
intensity-modulated radiation therapy |
16 |
|
radiotherapy |
16 |
|
cancer susceptibility genes |
13 |
|
early-age onset |
13 |
|
gastric cancer |
13 |
|
mst1r |
13 |
|
non-small cell lung cancer |
13 |
|
prognostic factors |
13 |
|
targeted therapy |
13 |
|
apobec-mediated signature |
12 |
|
nf-κb signaling |
12 |
|
somatic mutation landscape |
12 |
|
chemoradiotherapy |
11 |
|
liquid biopsy |
11 |
|
oncology |
11 |
|
arhgap fusions |
10 |
|
biobank |
10 |
|
drug screening |
10 |
|
ebv genome |
10 |
|
heterogeneity |
10 |
|
medical sciences |
10 |
|
neoadjuvant therapy |
10 |
|
oesophageal cancer |
10 |
|
organoid culture |
10 |
|
plasma ebv dna |
10 |
|
prognosis |
10 |
|
rhoa mutations |
10 |
|
transcriptome sequencing |
10 |
|
chinese |
9 |
|
chromatin accessibility |
9 |
|
epstein-barr virus |
9 |
|
esophageal cancer |
9 |
|
esophageal squamous cell carcinoma |
9 |
|
host-virus interaction |
9 |
|
leucocyte telomere length |
9 |
|
npc risk |
9 |
|
prognostic marker |
9 |
|
recursive partitioning analysis |
9 |
|
stage classification |
9 |
|
survival prediction |
9 |
|
telomere biology |
9 |
|
tumor microenvironment |
9 |
|
whole-genome bisulfite sequencing |
9 |
|
circulating neoplastic cell |
8 |
|
circulating tumor dna |
8 |
|
colorectal cancer |
8 |
|
hypothyroidism |
8 |
|
longitudinal real-time monitoring |
8 |
|
metastatic colorectal cancer |
8 |
|
neoadjuvant chemoradiotherapy |
8 |
|
nomogram |
8 |
|
non-invasive biomarker |
8 |
|
non-metastatic |
8 |
|
non-small-cell lung cancer |
8 |
|
oesophageal squamous cell carcinoma |
8 |
|
oesophagectomy |
8 |
|
palliative care |
8 |
|
advanced escc |
7 |
|
azygos vein blood |
7 |
|
cell-free dna |
7 |
|
checkpoint inhibitors |
7 |
|
circulating tumor cells |
7 |
|
circulating tumor cells (ctc) |
7 |
|
ctc clusters |
7 |
|
ctc enumeration |
7 |
|
early prediction |
7 |
|
emt |
7 |
|
epidermal growth factor receptor |
7 |
|
immune checkpoint inhibitors |
7 |
|
tyrosine kinase inhibitors |
7 |
|
cancer |
6 |
|
capecitabine |
6 |
|
cetuximab |
6 |
|
computed tomography |
6 |
|
concurrent chemoradiotherapy |
6 |
|
decision-making |
6 |
|
deep learning |
6 |
|
dosimetric predictors |
6 |
|
economic evaluation |
6 |
|
economic evidence |
6 |
|
esophagectomy |
6 |
|
follow up |
6 |
|
half-life clearance |
6 |
|
health care |
6 |
|
hepatocellular carcinoma |
6 |
|
immunotherapy |
6 |
|
local clinical remission |
6 |
|
magnetic resonance imaging |
6 |
|
metastatic |
6 |
|
multidisciplinary |
6 |
|
palliative |
6 |
|
plasma epstein–barr virus deoxyribonucleic acid |
6 |
|
positron emission tomography |
6 |
|
post-treatment plasma ebv dna |
6 |
|
postradiation malignancies |
6 |
|
prognostic factor |
6 |
|
prognostication |
6 |
|
quality of life |
6 |
|
radiogenomic |
6 |
|
radiomics |
6 |
|
simulation models |
6 |
|
survivorship |
6 |
|
thyroid cancer |
6 |
|
treatment outcomes |
6 |
|
5-fluorouracil |
5 |
|
aetiology |
5 |
|
cancer outcomes |
5 |
|
cancer site-standardized relative survival |
5 |
|
cheung chau island |
5 |
|
diffusion weighted imaging |
5 |
|
diffusion-weighted imaging |
5 |
|
efficacy |
5 |
|
esophageal cancer surgery |
5 |
|
global health |
5 |
|
health economics |
5 |
|
her2+ breast cancer |
5 |
|
her2-targeted therapy |
5 |
|
hong kong |
5 |
|
igra |
5 |
|
incidence |
5 |
|
induction chemotherapy |
5 |
|
intravoxel incoherent motion |
5 |
|
metastatic brain tumours |
5 |
|
metronomic |
5 |
|
mortality |
5 |
|
neoadjuvant chemoradiation |
5 |
|
network meta-analysis |
5 |
|
oral cyclophosphamide |
5 |
|
pooled analysis |
5 |
|
radiation therapy |
5 |
|
radiology and nuclear medicine |
5 |
|
recurrent |
5 |
|
staging |
5 |
|
stretched exponential |
5 |
|
surgery |
5 |
|
survival outcome |
5 |
|
systemic treatment |
5 |
|
tuberculosis reactivation |
5 |
|
tumour staging |
5 |
|
tyrosine kinase inhibitor |
5 |
|
acceptance |
4 |
|
anxiety |
4 |
|
assessment |
4 |
|
biomarker |
4 |
|
cisplatin |
4 |
|
colorectal liver metastasis |
4 |
|
combination therapy |
4 |
|
covid-19 |
4 |
|
cytology and histology |
4 |
|
dynamic contrast enhanced |
4 |
|
hepatectomy |
4 |
|
high dose rate endorectal brachytherapy |
4 |
|
hyperfractionation |
4 |
|
immune checkpoint inhibitor |
4 |
|
immune-related endocrine dysfunction |
4 |
|
liver metastases |
4 |
|
locally advanced recurrence |
4 |
|
malignancy |
4 |
|
manual contouring |
4 |
|
medically inoperable |
4 |
|
neoplasm metastasis |
4 |
|
oncology medical sciences |
4 |
|
post-chemoradiation fibrosis |
4 |
|
prediction |
4 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
4 |
|
re-irradiation |
4 |
|
recist |
4 |
|
rectal brachytherapy |
4 |
|
rectal cancer |
4 |
|
refractory |
4 |
|
regorafenib |
4 |
|
s-1 (combination) |
4 |
|
squamous cell carcinoma |
4 |
|
standard fractionation |
4 |
|
stomach neoplasms |
4 |
|
survivor |
4 |
|
target therapy |
4 |
|
toxicities |
4 |
|
toxicity |
4 |
|
treatment |
4 |
|
trifluridine/tipiracil (tas-102) |
4 |
|
tumor staging |
4 |
|
vaccination |
4 |
|
volumetric evaluation |
4 |
|
18f-fdg pet |
3 |
|
accuracy |
3 |
|
active surveillance |
3 |
|
advanced cancer |
3 |
|
afatinib |
3 |
|
aflibercept |
3 |
|
bevacizumab |
3 |
|
brachytherapy |
3 |
|
carcinoma |
3 |
|
carotid arteries |
3 |
|
cervical esophageal cancer |
3 |
|
chinese herbal medicine |
3 |
|
colorectal neoplasms |
3 |
|
complete metabolic response |
3 |
|
ct contrast |
3 |
|
do-not-resuscitate |
3 |
|
dose calculation |
3 |
|
dysphagia |
3 |
|
end of life |
3 |
|
epidermal growth factor receptor mutation |
3 |
|
epidermal growth factor; stevens-johnson syndrome |
3 |
|
erlotinib |
3 |
|
hcc diagnosis |
3 |
|
hepatotoxicity |
3 |
|
intensity modulated radiotherapy |
3 |
|
international atomic energy agency (iaea) |
3 |
|
kras wild-type |
3 |
|
laryngeal preservation |
3 |
|
liver toxicity |
3 |
|
low-middle income countries |
3 |
|
machine learning |
3 |
|
metastatic colorectal carcinoma |
3 |
|
mirna signature |
3 |
|
nasopharyngeal cancer (npc) |
3 |
|
nasopharyngectomy |
3 |
|
nephrotic syndrome |
3 |
|
non-small-cell lung; receptor |
3 |
|
proteinuria |
3 |
|
radiation recall |
3 |
|
radiotherapy access |
3 |
|
rucam |
3 |
|
standard of care |
3 |
|
systemic therapy |
3 |
|
thyroid |
3 |
|
traditional chinese medicine |
3 |
|
tyrosine-kinase inhibitor |
3 |
|
adenocarcinoma |
2 |
|
bmp antagonist |
2 |
|
breast cancer |
2 |
|
cancer incidence |
2 |
|
cancer mortality |
2 |
|
cancer patient |
2 |
|
cancer survival |
2 |
|
communication |
2 |
|
conditional survival |
2 |
|
cytokine |
2 |
|
docetaxel |
2 |
|
dpyd variant |
2 |
|
esophageal |
2 |
|
esophageal adenocarcinoma |
2 |
|
esophagogastric |
2 |
|
esophagogastric junction adenocarcinoma |
2 |
|
fluoropyrimidines |
2 |
|
gastric cancer progression |
2 |
|
gastrointestinal surgery |
2 |
|
intervention |
2 |
|
jnk inhibition |
2 |
|
lung dosimetric factors |
2 |
|
neoadjuvant |
2 |
|
novel |
2 |
|
pd-1 |
2 |
|
perioperative |
2 |
|
pharmacogenetics |
2 |
|
precision medicine |
2 |
|
preoperative |
2 |
|
radiation esophagitis |
2 |
|
radiation-induced lung fibrosis |
2 |
|
radiology |
2 |
|
sostdc1 |
2 |
|
support vector machine |
2 |
|
terminal care |
2 |
|
tumor immune microenvironment |
2 |
|
asia |
1 |
|
chemotherapy, adjuvant |
1 |
|
epidermal growth factor receptor (egfr)-specific monoclonal antibody |
1 |
|
hematology |
1 |
|
kras |
1 |
|
oxaliplatin |
1 |
|
radiation-induced liver disease |
1 |
|
receptor, epidermal growth factor |
1 |
|
rectal neoplasms |
1 |
|
stereotactic body radiation therapy |
1 |
|
supportive care |
1 |
|
vascular epidermal growth factor |
1 |
